Gangliosides and Guillain-Barré syndrome: the Spanish data.
Although ganglioside administration has been suspected as being responsible for Guillain-Barré syndrome (GBS) and peripheral neuropathies in some patients, current epidemiological, experimental, and clinical data do not support such an association. In Spain, a total of 17 cases of suspected GBS and neuropathy had been reported to the National Drug Surveillance System as of April 15, 1992. No definite relationship between ganglioside administration and the illness in these cases could be established after careful review of available data.
Díez-Tejedor
E
E
Department of Neurology, Hospital La Paz, Universidad Autonoma, Madrid, Spain.
Gutiérrez-Rivas
E
E
Gil-Peralta
A
A
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000276:immunology; D003711:Demyelinating Diseases / Q000209:etiology; D005260:Female; D005732:Gangliosides / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy; D010291:Paresis / Q000188:drug therapy; D011115:Polyneuropathies / Q000175:diagnosis / Q000188:drug therapy; D011129:Polyradiculoneuropathy / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D013030:Spain / Q000453:epidemiology
D000906:Antibodies; D005732:Gangliosides